Ms Furberg has more than 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President Rare Disease EMEA at Sanofi Genzyme, which she joined in 2002. She opened the first operation for Genzyme in the Nordic region and has also had responsibility for Genzyme in the Benelux region. Prior to Genzyme, Ms Furberg spent 15 years at Baxter in various business roles of increasing seniority, before which she was involved in the start-up of Pharmalink. She is currently a Non-executive Director at BerGenBio and has held board memberships at Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA, Probi AB and Copenhagen Capacity. She holds a Master of Science degree in Chemistry from the University of Oslo.

 Chemistry